Log in
(Ad)
Its partners include AT&T, Verizon, Sprint and T-Mobile.

It owns more than 200 patents.

And analysts say it has "home-run potential."

Yet this 5G superstock trades for only $5 a share.

NASDAQ:VRNA - VERONA PHARMA P/S Stock Price, Forecast & News

$5.75
-0.16 (-2.71 %)
(As of 01/21/2020 03:22 AM ET)
Add
Compare
Today's Range
$5.65
Now: $5.75▼
$5.94
50-Day Range
$3.82
MA: $5.10▼
$7.23
52-Week Range
$3.65
Now: $5.75▼
$12.89
Volume203,171 shs
Average Volume666,053 shs
Market Capitalization$75.73 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.78
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VRNA
Previous Symbol
CUSIPN/A
CIK1657312
Webhttp://www.veronapharma.com/
Phone44-20-3283-4200

Debt

Debt-to-Equity Ratio0.02
Current Ratio4.07
Quick Ratio4.07

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$6.40 per share
Price / Book0.90

Profitability

EPS (Most Recent Fiscal Year)($2.02)
Net Income$-26,560,000.00
Net MarginsN/A
Return on Equity-50.99%
Return on Assets-42.33%

Miscellaneous

Employees22
Outstanding Shares13,170,000
Market Cap$75.73 million
Next Earnings Date2/25/2020 (Estimated)
OptionableNot Optionable

Receive VRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:VRNA Rates by TradingView

(Ad)


Each week, an exclusive group of investors receives access to a simple list of 3 stocks to put on their radar for the week ahead.

You can sign up today to receive access to next week's watchlist -- generated by a proprietary methodology -- at no cost or obligation.

VERONA PHARMA P/S (NASDAQ:VRNA) Frequently Asked Questions

What is VERONA PHARMA P/S's stock symbol?

VERONA PHARMA P/S trades on the NASDAQ under the ticker symbol "VRNA."

How were VERONA PHARMA P/S's earnings last quarter?

VERONA PHARMA P/S (NASDAQ:VRNA) issued its earnings results on Tuesday, November, 5th. The company reported ($0.95) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.89) by $0.06. View VERONA PHARMA P/S's Earnings History.

When is VERONA PHARMA P/S's next earnings date?

VERONA PHARMA P/S is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for VERONA PHARMA P/S.

What price target have analysts set for VRNA?

3 Wall Street analysts have issued twelve-month price objectives for VERONA PHARMA P/S's shares. Their forecasts range from $17.00 to $60.00. On average, they anticipate VERONA PHARMA P/S's share price to reach $37.00 in the next twelve months. This suggests a possible upside of 543.5% from the stock's current price. View Analyst Price Targets for VERONA PHARMA P/S.

What is the consensus analysts' recommendation for VERONA PHARMA P/S?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VERONA PHARMA P/S in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VERONA PHARMA P/S.

Has VERONA PHARMA P/S been receiving favorable news coverage?

Headlines about VRNA stock have been trending positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. VERONA PHARMA P/S earned a daily sentiment score of 3.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the next few days. View News Stories for VERONA PHARMA P/S.

Are investors shorting VERONA PHARMA P/S?

VERONA PHARMA P/S saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 171,900 shares, an increase of 34,280.0% from the December 15th total of 500 shares. Based on an average daily volume of 123,400 shares, the days-to-cover ratio is presently 1.4 days. Approximately 2.2% of the company's shares are sold short. View VERONA PHARMA P/S's Current Options Chain.

Who are some of VERONA PHARMA P/S's key competitors?

What other stocks do shareholders of VERONA PHARMA P/S own?

Who are VERONA PHARMA P/S's key executives?

VERONA PHARMA P/S's management team includes the folowing people:
  • Dr. Jan-Anders Karlsson, CEO & Exec. Director (Age 64)
  • Mr. Piers John Morgan, Chief Financial Officer (Age 53)
  • Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA, Gen. Counsel (Age 52)
  • Ms. Victoria Stewart, Director of Communications
  • Dr. Peter Spargo, Sr. VP of Chemistry Manufacturing & Controls (Age 57)

When did VERONA PHARMA P/S IPO?

(VRNA) raised $61 million in an IPO on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

Who are VERONA PHARMA P/S's major shareholders?

VERONA PHARMA P/S's stock is owned by many different of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.62%).

Which major investors are buying VERONA PHARMA P/S stock?

VRNA stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..

How do I buy shares of VERONA PHARMA P/S?

Shares of VRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is VERONA PHARMA P/S's stock price today?

One share of VRNA stock can currently be purchased for approximately $5.75.

How big of a company is VERONA PHARMA P/S?

VERONA PHARMA P/S has a market capitalization of $75.73 million. The company earns $-26,560,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. VERONA PHARMA P/S employs 22 workers across the globe.View Additional Information About VERONA PHARMA P/S.

What is VERONA PHARMA P/S's official website?

The official website for VERONA PHARMA P/S is http://www.veronapharma.com/.

How can I contact VERONA PHARMA P/S?

VERONA PHARMA P/S's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company can be reached via phone at 44-20-3283-4200 or via email at [email protected]


MarketBeat Community Rating for VERONA PHARMA P/S (NASDAQ VRNA)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  235 (Vote Outperform)
Underperform Votes:  111 (Vote Underperform)
Total Votes:  346
MarketBeat's community ratings are surveys of what our community members think about VERONA PHARMA P/S and other stocks. Vote "Outperform" if you believe VRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Featured Article: What are gap-down stocks?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel